<DOC>
	<DOCNO>NCT00087646</DOCNO>
	<brief_summary>This 4 arm study design patient CHC respond peginterferon alfa-2b ( 12KD ) /ribavirin combination therapy . In patient , effect lengthen duration treatment , well include initial 12-week period high-dose PEGASYS ( 360 microgram sc ) , compare standard combination therapy PEGASYS ( 180 microgram sc ) ribavirin ( 1000-1200mg po ) . The anticipated time study treatment 1-2 year target sample size 500+ individual .</brief_summary>
	<brief_title>REPEAT Study - A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Therapy Combination With COPEGUS ( Ribavirin ) Patients With Chronic Hepatitis C ( CHC ) Who Did Not Respond Previous PegIntron ( Peginterferon Alfa-2b ( 12KD ) ) /Ribavirin Combination Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient &gt; =18 year age ; CHC infection ; liver biopsy ( &lt; 24 calendar month first dose ) , result consistent CHC infection ; use 2 form contraception study 6 month study men woman ; Lack response previous treatment peginterferon alfa2b ( 12KD ) /ribavirin combination therapy give &gt; =12 week . woman pregnant breastfeeding ; male partner woman pregnant ; condition associate decompensated liver disease ; form liver disease , include liver cancer ; human immunodeficiency virus infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>